Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,046 | -30,836 | -25,336 | -17,152 | -9,631 |
| Depreciation Amortization | 12 | 53 | 12 | 12 | 10 |
| Other Working Capital | 1,309 | 609 | 1,790 | 64 | 1,092 |
| Other Operating Activity | -141 | 6,299 | 5,701 | 2,785 | 840 |
| Operating Cash Flow | $-3,866 | $-23,875 | $-17,833 | $-14,291 | $-7,689 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 21,000 | 11,000 | 11,000 | N/A |
| Common Stock Issued | 257 | 5,475 | 3,238 | 1,942 | N/A |
| Financing Cash Flow | $257 | $26,475 | $14,238 | $12,942 | $0 |
| Beginning Cash Position | 17,720 | 15,120 | 15,120 | 15,120 | 15,120 |
| End Cash Position | 14,111 | 17,720 | 11,525 | 13,771 | 7,431 |
| Net Cash Flow | $-3,609 | $2,600 | $-3,595 | $-1,349 | $-7,689 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,866 | -23,875 | -17,833 | -14,291 | -7,689 |
| Free Cash Flow | -3,866 | -23,875 | -17,833 | -14,291 | -7,689 |